Roche isn’t done lin­ing up new col­lab­o­ra­tions in the hot field of drug­ging RNA. Here’s one more

Roche has a big ap­petite for all things in­volv­ing drug­ging RNA. And they just or­dered a fresh help­ing to see if they can start to sa­ti­ate the hunger.

Last April Roche BD chief James Sabry signed off on a $190 mil­lion up­front to get start­ed on a col­lab­o­ra­tion with Ar­rakis, the start­up from Mike Gilman that cre­at­ed one of the pi­o­neers in the space. That fol­lowed a deal with Bill Haney’s Sky­hawk, an­oth­er up­start look­ing to drug the un­drug­gable by way of RNA. And to­day it’s Ri­bometrix’s turn, which snares a $25 mil­lion cash down pay­ment from Genen­tech and more than a bil­lion dol­lars in mile­stones for big-pic­ture suc­cess.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER